Deals In Depth: March 2019
Executive Summary
Alexion signed two $600m-plus alliances, with Zealand Pharma and Affibody, that made it into the top five deals by value. Thermo Fisher grew its capabilities in cell and gene therapy manufacturing by acquiring Brammer Bio for $1.7bn. A $3.5bn private placement by AstraZeneca boosted pharma financing.